Quanterix
Quanterix's revenue rose 1.1% to $139 million in fiscal 2025. Its operating margin was −90.4%, down from −38.3% a year earlier. Free cash flow was −$80 million. The diluted share count rose 11.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Quanterix lost money in fiscal 2025: a net loss of $107 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 396 | 339 | 181 | 57 | 118 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −145.3x | — | — | — | — |
| Current ratio | 12.1x | 12.2x | 9.8x | 8.7x | 2.8x |
| Quick ratio | 11.5x | 11.6x | 9.1x | 7.9x | 2.1x |
Cash flow
Projections
Project Quanterix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Quanterix says to expect
- Full year 2026: adjusted gross margin
The Company continues to expect adjusted gross margins (non-GAAP) in a range of 48-50%.
- End of 2026: cash balance
Quanterix now expects to end 2026 with a cash balance of approximately $70 million, and no debt.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $296,049 of Quanterix shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | William P DonnellyDirector | Bought | 72,245 | $2.93 | $211,678 | Form 4 |
| Aug 12, 2026 | William P DonnellyDirector | Bought | 27,155 | $2.75 | $74,676 | Form 4 |
| May 12, 2026 | Benjamin MeadowsChief Commercial Officer | Bought | 3,500 | $2.77 | $9,695 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −2.6% | −15.7% | −56.4% |
| Altman Z'' | 5.92 | 5.08 | −1.83 |
| Accruals ratio | −2.2% | −0.8% | −7.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Quanterix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Quanterix | FY25 | 1.1% | −90.4% | −57.5% | — | — | — | |
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | Compare |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 18 | 23 | 38 | 57 | 86 | 111 | 106 | 122 | 137 | 139 |
| Revenue growth | — | 30.1% | 64.5% | 50.8% | 52.2% | 28.0% | −4.5% | 16.0% | 12.3% | 1.1% |
| Gross profit | 8 | 10 | 18 | 27 | 48 | 65 | 45 | 74 | 83 | 65 |
| Research and development | 17 | 16 | 16 | 16 | 20 | 28 | 27 | 26 | 31 | 36 |
| Operating income | −22 | −26 | −32 | −42 | −32 | −56 | −104 | −46 | −53 | −126 |
| Net income | −23 | −27 | −32 | −41 | −32 | −56 | −100 | −28 | −38 | −107 |
| Diluted EPS (US$) | — | — | — | −1.63 | −1.07 | −1.54 | −2.69 | −0.75 | −1.00 | −2.51 |
| Diluted shares (millions) | 2 | 4 | 22 | 25 | 30 | 36 | 37 | 38 | 38 | 43 |
| Cash flow | ||||||||||
| Cash from operations | −18 | −22 | −29 | −26 | −23 | −48 | −49 | −19 | −35 | −77 |
| Capital expenditure | 0 | 1 | 2 | 11 | 4 | 14 | 12 | 4 | 3 | 3 |
| Free cash flow | −18 | −23 | −30 | −37 | −27 | −61 | −60 | −23 | −39 | −80 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 4 | 14 | 0 | 0 | 0 | 0 | 0 | 93 |
| Stock-based compensation | 1 | 2 | 5 | 6 | 10 | 16 | 15 | 17 | 20 | 21 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 30 | 80 | 44 | 109 | 182 | 396 | 339 | 181 | 57 | 118 |
| Debt incl. finance leases | — | 9 | 8 | 8 | 8 | — | — | — | — | — |
| Total assets | — | 92 | 68 | 170 | 271 | 502 | 434 | 429 | 406 | 419 |
| Total liabilities | — | 26 | 26 | 41 | 65 | 61 | 76 | 79 | 76 | 123 |
| Shareholders' equity | −115 | 66 | 41 | 129 | 206 | 443 | 358 | 350 | 330 | 296 |
| Margins and ratios | ||||||||||
| Gross margin | 44.1% | 43.7% | 47.7% | 47.3% | 55.8% | 58.6% | 43.0% | 60.7% | 60.5% | 46.8% |
| Operating margin | −123.5% | −113.7% | −83.8% | −73.3% | −36.6% | −51.1% | −98.8% | −37.6% | −38.3% | −90.4% |
| Net margin | −131.8% | −118.1% | −83.8% | −71.9% | −36.5% | −50.2% | −94.4% | −23.2% | −28.0% | −77.1% |
| Free cash flow margin | −103.9% | −101.6% | −80.3% | −65.3% | −31.6% | −55.4% | −57.1% | −18.5% | −28.0% | −57.5% |
| Rule of 40 (growth + FCF margin) | — | −71.5% | −15.8% | −14.5% | 20.6% | −27.4% | −61.6% | −2.6% | −15.7% | −56.4% |
| Return on capital | — | — | — | −208.1% | −84.4% | — | — | — | — | — |
| Return on equity | — | — | −59.0% | −48.1% | −18.9% | −17.1% | −24.9% | −8.0% | −11.3% | −34.2% |
| Return on assets | — | — | −39.6% | −34.4% | −14.3% | −14.4% | −21.3% | −6.6% | −9.2% | −26.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |